ASCO and EHA highlights in myeloma and AL amyloidosis

The American Society of Clinical Oncology Annual Meeting (ASCO2020) is the largest and one of the most important congresses for the oncology community. Many myeloma and AL amyloidosis updates were presented at this congress which was held from 29 to 31 May 2020. Two weeks later, the 25th edition of the European Hematology Association’s annual congress (EHA25 Virtual), one of the most important haematology congresses here in Europe, was held from 11 June to 21…

EHA 25 Virtual – Myeloma highlights

  Data of new combinations not only in relapsed and refractory myeloma but also in upfront settings were presented in the European Hematology Association (EHA) Annual congress, held virtually from 11 June to 21 June 2020. Myeloma Patients Europe (MPE) has interviewed Dr Maria-Victoria Mateos, Director of the Myeloma Unit at University Hospital of Salamanca-IBSAL, in Spain, to summarise the most important updates presented at this meeting for the treatment of myeloma patients.

EHA25 Virtual – AL amyloidosis highlights

  Although currently there are not approved drugs for the treatment of AL amyloidosis, important data were presented in the European Hematology Association (EHA) Annual congress, held virtually from 11 June to 21 June 2020. Myeloma Patients Europe (MPE) has interviewed Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel), and one of the authors of the ANDROMEDA study, to summarise the most important updates presented at this meeting for the treatment of the…

ASCO 2020 myeloma highlights

  The largest, and one of the most important, oncology meetings in the calendar year, the American Society of Clinical Oncology (ASCO) annual scientific meeting, was held from 29 to 31 May. Myeloma Patients Europe attended this virtual meeting and interviewed Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, to summarise the most important myeloma highlights presented at ASCO20.